NCT05389423 2026-02-19
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
National Institutes of Health Clinical Center (CC)
Regeneron Pharmaceuticals
The Affiliated People's Hospital of Ningbo University
New York Medical College
New York Medical College
Federal Research Institute of Pediatric Hematology, Oncology and Immunology